RecruitingNCT02820233
Studies of Neuregulin/ERBB Signaling in Human Heart
Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells
Sponsor
Douglas B. Sawyer
Enrollment
80 participants
Start Date
Jun 1, 2015
Study Type
OBSERVATIONAL
Conditions
Summary
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.
Exclusion Criteria9
- less than 18 years of age
- unwilling or unable to provide informed consent
- known active myocarditis
- hypertrophic cardiomyopathy
- constrictive pericarditis or other significant pericardial disease
- severe pulmonary hypertension
- significant renal impairment (Cr \> 2.5 mg/dL)
- severe ventricular arrhythmias
- pregnancy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02820233
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations